ß-Adrenergic blockade combined with subcutaneous B-type natriuretic peptide: A promising approach to reduce ventricular arrhythmia in heart failure?

Heart

Volumn 100, Issue 11, 2014, Pages 833-841

  Thireau, Jérôme ^a   Karam, Sarah ^a   Roberge, Stéphanie ^a   Roussel, Julien ^a   Aimond, Franck ^a   Cassan, Cécile ^a   Le Guennec, Jean Yves ^a   Lacampagne, Alain ^a   Fauconnier, Jérémy ^a   Richard, Sylvain ^a   Gac, Arnaud ^b   Babuty, Dominique ^c  

^a UNIVERSITY OF MONTPELLIER   (France)

^b Adinstruments Limited   (United Kingdom)

^c SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

14 5 30A; BRAIN NATRIURETIC PEPTIDE; CALCIUM ION; METOPROLOL; PROTEIN S 100; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NATRIURETIC FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAM; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART FUNCTION; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; P WAVE; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; R WAVE; ANIMAL; ARRHYTHMIAS; AUTONOMIC NERVOUS SYSTEM; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; ELECTROCARDIOGRAPHY; HEART VENTRICLE TACHYCARDIA; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHARMACOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ARRHYTHMIAS; AUTONOMIC NERVOUS SYSTEM; HEART FAILURE; PHARMACOLOGY;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; HEART FAILURE; INJECTIONS, SUBCUTANEOUS; MALE; METOPROLOL; MICE; MICE, INBRED C57BL; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84900325741     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-305167     Document Type: Article

References (30)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125: e2-220.
2. Ikeda Y, Hoshijima M, Chien KR. Toward biologically targeted therapy of calcium cycling defects in heart failure. Physiology (Bethesda) 2008;23:6-16.
3. Thireau J, Karam S, Fauconnier J, et al. Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity. Cardiovasc Res 2012;95:59-68.
4. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
5. Aronson D, Burger AJ. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 2004;148:e16.
6. Azevedo ER, Newton GE, Parker AB, et al. Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure. J Cardiovasc Pharmacol 2000;35:129-35.
7. Chan NY, Seyedi N, Takano K, et al. An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase G-mediated phosphodiesterase type 3 inhibition. Circulation 2012;125:298-307.
8. Qvigstad E, Moltzau LR, Aronsen JM, et al. Natriuretic peptides increas beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 2010;85:763-72.
9. Chen HH, Glockner JF, Schirger JA, et al. Novel protein therapeutics for systolic heart failure: Chronic subcutaneous B-Type natriuretic peptide. J Am Coll Cardiol 2012;60:2305-12.
10. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005;112: e154-235.
11. Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: Beta blockers are associated with a reduction in QT dispersion. Heart 1999;81:297-302.
12. Volkers M, Loughrey CM, Macquaide N, et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2007;41:135-43.
13. Most P, Remppis A, Pleger ST, et al. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007;293:R568-77.
14. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
15. Cataliotti A, Tonne JM, Bellavia D, et al. Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation 2011;123:1297-305.
16. Pan Y, Zhu W, Ma J, et al. Therapeutic effects of continuous infusion of brain natriuretic peptides on postmyocardial infarction ventricular remodelling in rats. Arch Cardiovasc Dis 2011;104:17-28.
17. He J, Chen Y, Huang Y, et al. Effect of long-term B-type natriuretic peptide treatment on left ventricular remodeling and function after myocardial infarction in rats. Eur J Pharmacol 2009;602:132-7.
18. George I, Xydas S, Klotz S, et al. Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model. J Cardiovasc Pharmacol 2010;55:14-20.
19. Chan NY, Robador PA, Levi R. Natriuretic peptide-induced catecholamine release from cardiac sympathetic neurons: inhibition by histamine H3 and H4 receptor activation. J Pharmacol Exp Ther 2012;343:568-77.
20. Springer J, Azer J, Hua R, et al. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J Mol Cell Cardiol 2012;52:1122-34.
21. Dickey DM, Flora DR, Bryan PM, et al. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007;148:3518-22.
22. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34:155-62.
23. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
24. Hinterseer M, Beckmann BM, Thomsen MB, et al. Usefulness of short-term variability of QT intervals as a predictor for electrical remodeling and proarrhythmia in patients with nonischemic heart failure. Am J Cardiol 2010;106:216-20
25. Cheng H, Lederer WJ. Calcium sparks. Physiol Rev 2008;88:1491-545.
26. Fauconnier J, Thireau J, Reiken S, et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 2010;107:1559-64.
27. Brinks H, Rohde D, Voelkers M, et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 2011;58:966-73.
28. Mangiafico S, Costello-Boerrigter LC, Andersen IA, et al. Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics. Eur Heart J 2013;34:886c-93c.
29. von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-Angiotensin blockade combined with natriuretic Peptide system augmentation: Novel therapeutic concepts to combat heart failure. Circ Heart Fail 2013; 6:594-605.
30. Coumel P. Cardiac arrhythmias and the autonomic nervous system. J Cardiovasc Electrophysiol 1993;4:338-55.